56798-34-6

Basic information

• Product Name: 2',4-DIHYDROXY-4',6'-DIMETHOXYCHALCONE
• Synonyms: 2',4-DIHYDROXY-4',6'-DIMETHOXYCHALCONE;1-(2-HYDROXY-4,6-DIMETHOXYPHENYL)-3-(4-HYDROXYPHENYL)-2-PROPEN-1-ONE;4,2'-DIHYDROXY-4',6'-DIMETHOXYCHALCONE;4,2'-DIHYDROXY-4',6'-DIMETHYLCHALCONE;FLAVOKAWAIN;(E)-1-(2-HYDROXY-4,6-DIMETHOXYPHENYL)-3-(4-HYDROXYPHENYL)PROP-2-EN-1-ONE;DIHYDROXY-4',6'-DIMETHOXYCHALCONE, 2',4-;4-Hydroxybenzylidene(4,6-dimethoxy-2-hydroxyacetophenone)
• CAS NO: 56798-34-6
• Molecular Formula: C₁₇H₁₆O₅
• Molecular Weight: 300.31
• EINECS: 200-258-5
• Product Categories: Chalcones
• Mol File: 56798-34-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 194-196°C
• Boiling Point: 556 °C at 760 mmHg
• Flash Point: 207.2 °C
• Appearance: /
• Density: 1.279 g/cm³
• CAS DataBase Reference: 2',4-DIHYDROXY-4',6'-DIMETHOXYCHALCONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2',4-DIHYDROXY-4',6'-DIMETHOXYCHALCONE(56798-34-6)
• EPA Substance Registry System: 2',4-DIHYDROXY-4',6'-DIMETHOXYCHALCONE(56798-34-6)

Safety Data

• Hazardous Substances Data: 56798-34-6(Hazardous Substances Data)

Usage

General Description

2',4-Dihydroxy-4',6'-dimethoxychalcone is a natural compound belonging to the class of chalcones. It is found in various plant sources and has been studied for its potential pharmacological activities. Research has suggested that 2',4-Dihydroxy-4',6'-dimethoxychalcone may possess antioxidant, anti-inflammatory, and anti-cancer properties. It has also shown potential in the treatment of metabolic disorders and cardiovascular diseases. Additionally, this compound has been investigated for its ability to inhibit the activity of certain enzymes involved in disease progression and has shown promise as a therapeutic agent. Overall, 2',4-Dihydroxy-4',6'-dimethoxychalcone holds potential for various medicinal and therapeutic applications.

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 6515-21-5 4-methoxymethoxy-benzaldehyde 
• 77184-69-1 2’,4’-dimethoxy-6’-hydroxy-4-O-methoxymethylchalcone 

Downstream Products

• 1386981-14-1 4-(5,7-dimethoxy-4-oxochroman-2-yl)phenyl phenylcarbamate 
• 26207-67-0 2-(4-hydroxyphenyl)-5,7-dimethoxychroman-4-one 

Relevant articles and documents

Analogues of 2′-hydroxychalcone with modified C4-substituents as the inhibitors against human acetylcholinesterase

A series of C4-substituted tertiary nitrogen-bearing 2′-hydroxychalcones were designed and synthesised based on a previous mixed type acetylcholinesterase inhibitor. Majority of the 2′-hydroxychalcone analogues displayed a better inhibition against acetyl

Flavokawain derivative or pharmaceutically acceptable salt thereof having inhibitory activity on Hsp90 and medical use thereof

The present invention relates to a flavokawain derivative or a pharmaceutically acceptable salt thereof having an activity for inhibiting Hsp90 and a medical use thereof wherein the flavokawain derivative comprises good effect of inhibiting Hsp90 and accordingly leads to decomposition of Hsp 90 client protein causing diseases related to cancer or neurodegenerative diseases by inhibiting Hsp90, thereby being used in drug medicine and healthy food products for preventing or treating Hsp 90 which is a mediated disease like diseases related to cancer or neurodegenerative diseases.COPYRIGHT KIPO 2015

Antispasmodic activity of xanthoxyline derivatives: Structure-activity relationships

The antispasmodic activity of several xanthoxyline derivatives against acetylcholine-induced contraction of the guinea pig ileum was evaluated in vitro. The acetophenones with two methoxyl groups, mainly in the 3,4 positions, exhibited potent antispasmodic activity. Modification of the hydroxyl group in xanthoxyline by the introduction of benzoyl, acetyl, or tosyl groups produced inactive compounds, whereas the introduction of benzyl or p-methoxybenzyl groups furnished compounds that were four- to eight-fold more potent than xanthoxyline. In marked contrast, the introduction of a methyl group gave a compound that caused contractant activity. Modification of the carbonyl group of xanthoxyline lead to inactive compounds, whereas the condensation of xanthoxyline with benzaldehydes gave chalkones that were about fivefold more potent than xanthoxyline. The introduction of benzyl and styrene groups, on the basis of the similarity with papaverine, improves the antispasmodic action of the xanthoxyline derivatives. Our results suggest that the methoxyl and carbonyl groups are critical structural points for the antispasmodic activity of xanthoxyline derivatives. The hydroxyl group improves antispasmodic activity, but is not fundamental to its manifestation.